BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:23 PM
 | 
Aug 05, 2008
 |  BC Extra  |  Clinical News

YM reports nimotuzumab data

YM (TSX:YM; AMEX:YMI) said preliminary data from the open-label, Canadian Phase II YMB1000-015 trial showed that 400 mg of nimotuzumab per week plus irinotecan produced an objective response rate (ORR) of 3.4% in 58 evaluable irinotecan-refractory metastatic colorectal cancer (mCRC) patients. YM said the result was inferior to results...

Read the full 224 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >